WINT Windtree Therapeutics Dashboard

Windtree Therapeutics, Inc. engages in the manufacture and development of products for infants and respiratory diseases. It focuses on producing of surfactant replacement therapies for patients with respiratory disease and neonatology for the improvement of respiratory distress syndrome for infants. The company was founded by Evan Myrianthopoulos and James S. Kuo on November 6, 1992 and is headquartered in Warrington, PA.

Company profile

Ticker

WINT, WINTW

Exchange

NASDAQ

Website

www.windtreetx.com

CEO

Craig E. Fraser

Incorporated

Delaware

Location

Pennsylvania

Fiscal year end

Dec 31

Sector

Manufacturing > Biological Product (except Diagnostic) Manufacturing

Industry (SIC)

Biological Products, (No Diagnostic Substances)

AMGEN • Gilead Sciences • Biogen • Qiagen • Moderna • BioNTech SE • Bio-Techne • Enzon Pharmaceuticals • Denali Therapeutics • Allogene Therapeutics ...

Former names

ANSAN INC, ANSAN PHARMACEUTICALS INC, DISCOVERY LABORATORIES INC /DE/

SEC CIK

0000946486

Corporate docs

Articles of Incorporation & Bylaws

IRS number

943171943

WINT stock data

S&P 500

1M 1Y 2Y 5Y

News

Pro users get this 30m faster

Stocks That Hit 52-Week Lows On Friday

16 Apr 21

Before 10 a.m. ET Friday, 62 stocks made new 52-week lows.

Insider Buys Windtree Therapeutics Stock

6 Apr 21

12 Health Care Stocks Moving In Wednesday's Pre-Market Session

31 Mar 21

34 Stocks Moving in Wednesday's Pre-Market Session

31 Mar 21

Windtree Therapeutics Q4 EPS $(0.44) Down From $(0.16) YoY

29 Mar 21

Press releases

Pro users get this 30m faster

Thinking about buying stock in CASI Pharmaceuticals, Windtree Therapeutics, ChargePoint Holdings, FreightCar America, or AzurRx BioPharma?

31 Mar 21

NEW YORK, March 31, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for CASI, WINT, CHPT, RAIL, and AZRX.

Windtree Therapeutics Reports Fourth Quarter and Year End 2020 Financial Results and Provides Key Business Updates

29 Mar 21

WARRINGTON, Pa., March 29, 2021 /PRNewswire/ -- Windtree Therapeutics, Inc. (NasdaqCM: WINT), a biotechnology and medical device company focused on advancing multiple late-stage interventions for acute cardiovascular and

Windtree Therapeutics Announces Closing of $30.0 Million Public Offering

25 Mar 21

WARRINGTON, Pa., March 25, 2021 /PRNewswire/ -- Windtree Therapeutics, Inc. (NasdaqCM: WINT) ("Windtree" or the "Company"), a biotechnology and medical device company focused on advancing multiple

Windtree Therapeutics Announces Pricing of $30.0 Million Public Offering

23 Mar 21

Windtree Therapeutics Announces Proposed Public Offering of Common Stock and Warrants

22 Mar 21

Investment data

Data from SEC filings

Securities sold

Number of investors

Calendar

29 Mar 21

17 Apr 21

31 Dec 21

Financial summary

Financial statements Chart WINT financial data

Quarter (USD)	Dec 20	Sep 20	Jun 20	Mar 20
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Annual (USD)	Dec 20	Dec 19	Dec 18	Dec 17
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from company earnings reports.

Cash burn rate (estimated)	Burn method: Change in cash		Burn method: Operating income/loss		Burn method: FCF (opex + capex)
	Last Q	Avg 4Q	Last Q	Avg 4Q	Last Q	Avg 4Q
Cash on hand (at last report)	17.08M	17.08M	17.08M	17.08M	17.08M	17.08M
Cash burn (monthly)	1.76M	470.67K	2.32M	2.53M	1.51M	2.11M
Cash used (since last report)	6.27M	1.68M	8.27M	9.01M	5.39M	7.52M
Cash remaining	10.82M	15.41M	8.81M	8.08M	11.69M	9.56M
Runway (months of cash)	6.2	32.7	3.8	3.2	7.7	4.5

Beta Read what these cash burn values mean

Recent insider trades

WINT insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	$Price	#Shares	$Value	#Remaining
7 Apr 21	Eric Curtis	Common Stock	Buy	Aquire P	No	No	2.5172	791	1.99K	1,291
6 Apr 21	Fraser Craig	Common Stock	Buy	Aquire P	No	No	2.57	500	1.29K	28,298
5 Apr 21	Fraser Craig	Common Stock	Buy	Aquire P	No	No	2.5799	1,000	2.58K	27,798
1 Apr 21	Fraser Craig	Common Stock	Buy	Aquire P	No	No	2.4587	500	1.23K	26,798
31 Mar 21	Fraser Craig	Common Stock	Buy	Aquire P	No	No	2.3199	500	1.16K	26,298

Data from 3, 4 and 5 filings. Stock values as filed, not updated for current price.

Institutional ownership Q4 2020

WINT institutional ownership history Ownership history

Data for the last complete 13F reporting period. To see the most recent changes to ownership, click the ownership history button above.

2.7% owned by funds/institutions

13F holders	Current	Prev Q	Change
Total holders	15	15	–
Opened positions	2	5	-60.0%
Closed positions	2	2	–
Increased positions	1	1	–
Reduced positions	4	1	+300.0%

13F shares	Current	Prev Q	Change
Total value	3.64M	4M	-9.0%
Total shares	709.09K	727.33K	-2.5%
Total puts	0	0
Total calls	450K	0	NEW
Total put/call ratio	–	–	–

Largest owners	Shares	Value	Change
Vanguard	276.53K	$1.42M	+1.0%
Millennium Management	107.51K	$552K	-29.1%
Kepos Capital	90K	$462K	0.0%
NTRS Northern Trust	72.39K	$371K	-11.3%
Frontier Wealth Management	60K	$308K	0.0%
tru Independence	60K	$308K	NEW
Deerfield Management	20.15K	$103K	0.0%
Paloma Partners Management	18.47K	$95K	-50.2%
Tower Research Capital	3.58K	$19K	NEW
UBS UBS Group AG - Registered Shares	367	$2K	-82.0%

Largest transactions	Shares	Bought/sold	Change
tru Independence	60K	+60K	NEW
Millennium Management	107.51K	-44.2K	-29.1%
Paloma Partners Management	18.47K	-18.62K	-50.2%
GS Goldman Sachs	0	-10.91K	EXIT
NTRS Northern Trust	72.39K	-9.21K	-11.3%
Tower Research Capital	3.58K	+3.58K	NEW
Vanguard	276.53K	+2.79K	+1.0%
UBS UBS Group AG - Registered Shares	367	-1.67K	-82.0%
Cutler	0	-3	EXIT
WFC Wells Fargo & Co.	31	0	0.0%

Data from 13F filings. Stock values as filed, not updated for current price. Long positions only.

Financial report summary

Competition

Abbvie

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. junior Avg

New words: advocate, Africa, agenda, AMP, analogy, androstane, BARDA, bargaining, Baricitinib, BBA, Biden, Biomedical, Bipartisan, broaden, bulk, card, Cardiology, Carlo, ceiling, Changshu, commensurate, compelled, Congressional, contradictory, departure, dissemination, Distinguishing, donut, driven, endeavor, enrichment, EUA, Evan, exacerbated, exert, fight, filtration, fit, flux, gap, genuine, Gung, Hamill, heard, Hefei, heightened, HF, HFpEF, Hg, hole, home, hypoperfusion, hypothecate, illustrative, incentivizing, IVDR, Judge, Ladenburg, Leslie, lethal, lockup, Loh, MDR, mm, Monte, motivate, neutralizing, Oppenheimer, outlook, outreach, Overallotment, PF, PolyPeptide, presumption, problem, prompted, pure, ratably, ready, rebate, receptor, reengage, reinvest, Relief, remanded, remdesivir, reopening, repay, repayable, repayment, repealed, rescue, reward, rhythm, Robert, rural, safeguard, SciAnda, Scott, sequence, sequester, serotype, shift, solution, South, speed, stable, stimulating, subscription, syncytial, Taxpayer, Thalmann, theft, trillion, Trump, unconstitutional, underwriting, underwritten, undo, unusual, unwanted, vaccine, viral, virtual, workplace, write

Removed: accelerated, accelerating, accreted, achievable, Allergy, allocating, attached, categorized, circumvention, cisplatin, clinic, Codification, cold, Commonwealth, comprise, conserve, context, countermeasure, defer, division, Eleison, eligibility, encouraged, expressed, extinguished, Farmaceutici, feature, hereto, ILC, immaterial, incomplete, Inferior, inhaled, Joseph, Leone, lipid, Mahady, match, multiplied, NIAID, nonbinding, OTC, OTCQB, Overview, participant, powered, PRC, premise, proportionately, pursued, quotation, reader, refrigeration, restructure, retention, retired, retrospective, routinely, SBIR, SPA, Steering, Subtopic, tightly, traded, unaudited, verified, waived

From filing 10-K 2020 FY